Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | MAG | P20916 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658823 | 1.00 | SLC6A2 (0.45) | SLC6A2HRASLGALS9LGALS3LGALS1 | |
| SCHEMBL7642620 | 0.91 | SLC6A2 (0.44) | SLC6A2LGALS8 | |
| SCHEMBL7154227 | 0.91 | SLC6A2 (0.44) | SLC6A2LGALS8 | |
| SCHEMBL15955443 | 0.88 | SLC6A2 (0.39) | SLC6A2HRASLGALS9LGALS3LGALS1 | |
| SCHEMBL17173997 | 0.85 | SLC6A2 (0.43) | SLC6A2HRASLGALS3LGALS8MAG | |
| SCHEMBL5497489 | 0.83 | SLC6A2 (0.58) | SLC6A2HRASLGALS9LGALS3LGALS1 | |
| SCHEMBL5497498 | 0.83 | SLC6A2 (0.58) | SLC6A2HRASLGALS9LGALS3LGALS1 | |
| SCHEMBL6704224 | 0.83 | SLC6A2 (0.41) | SLC6A2LGALS8 | |
| SCHEMBL6701050 | 0.83 | SLC6A2 (0.41) | SLC6A2LGALS8 | |
| SCHEMBL7156144 | 0.83 | SLC6A2 (0.41) | SLC6A2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340654-A1 | CRYSTALLINE DIFUCOSYLLACTOSE | GLYCOM A/S (DK) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340654-A1 | CRYSTALLINE DIFUCOSYLLACTOSE | UGGT1, FUCA2, FUT6 | SLC6A2 2544/4885HRAS 3557/4885LGALS9 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.